These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27042012)

  • 1. Computational and nonglycosylated systems: a simpler approach for development of nanosized PEGylated proteins.
    Mirzaei H; Kazemi B; Bandehpour M; Shoari A; Asgary V; Ardestani MS; Madadkar-Sobhani A; Cohan RA
    Drug Des Devel Ther; 2016; 10():1193-200. PubMed ID: 27042012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, modeling, expression, and chemoselective PEGylation of a new nanosize cysteine analog of erythropoietin.
    Cohan RA; Madadkar-Sobhani A; Khanahmad H; Roohvand F; Aghasadeghi MR; Hedayati MH; Barghi Z; Ardestani MS; Inanlou DN; Norouzian D
    Int J Nanomedicine; 2011; 6():1217-27. PubMed ID: 21753873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, modeling, and expression of erythropoietin cysteine analogs in Pichia pastoris: improvement of mean residence times and in vivo activities through cysteine-specific PEGylation.
    Maleki A; Madadkar-Sobhani A; Roohvand F; Najafabadi AR; Shafiee A; Khanahmad H; Cohan RA; Namvar N; Tajerzadeh H
    Eur J Pharm Biopharm; 2012 Apr; 80(3):499-507. PubMed ID: 22068050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.
    Long DL; Doherty DH; Eisenberg SP; Smith DJ; Rosendahl MS; Christensen KR; Edwards DP; Chlipala EA; Cox GN
    Exp Hematol; 2006 Jun; 34(6):697-704. PubMed ID: 16728273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin.
    Wang YJ; Hao SJ; Liu YD; Hu T; Zhang GF; Zhang X; Qi QS; Ma GH; Su ZG
    J Control Release; 2010 Aug; 145(3):306-13. PubMed ID: 20427020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of bioactivity and pharmacokinetic characteristics of PEGylated P.pastoris-expressed erythropoietin.
    Maleki A; Najafabadi AR; Roohvand F; Shafiee A; Khanahmad H; Faghihi H; Hedayati MH; Tajerzadeh H
    Drug Deliv; 2011 Nov; 18(8):570-7. PubMed ID: 21892875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient preparation and PEGylation of recombinant human non-glycosylated erythropoietin expressed as inclusion body in E. coli.
    Wang YJ; Liu YD; Chen J; Hao SJ; Hu T; Ma GH; Su ZG
    Int J Pharm; 2010 Feb; 386(1-2):156-64. PubMed ID: 19932158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of site-specific ScFv PEGylation for tumor-targeting pharmaceuticals.
    Natarajan A; Xiong CY; Albrecht H; DeNardo GL; DeNardo SJ
    Bioconjug Chem; 2005; 16(1):113-21. PubMed ID: 15656582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
    Pan LQ; Wang HB; Lai J; Xu YC; Zhang C; Chen SQ
    Biomaterials; 2013 Dec; 34(36):9115-23. PubMed ID: 23981355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor.
    Doherty DH; Rosendahl MS; Smith DJ; Hughes JM; Chlipala EA; Cox GN
    Bioconjug Chem; 2005; 16(5):1291-8. PubMed ID: 16173810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cysteine-specific PEGylation of rhG-CSF via selenylsulfide bond.
    Kunstelj M; Fidler K; Skrajnar S; Kenig M; Smilović V; Kusterle M; Caserman S; Zore I; Porekar VG; Jevševar S
    Bioconjug Chem; 2013 Jun; 24(6):889-96. PubMed ID: 23600957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific PEGylation of hemoglobin at Cys-93(beta): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain.
    Manjula BN; Tsai A; Upadhya R; Perumalsamy K; Smith PK; Malavalli A; Vandegriff K; Winslow RM; Intaglietta M; Prabhakaran M; Friedman JM; Acharya AS
    Bioconjug Chem; 2003; 14(2):464-72. PubMed ID: 12643758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of sialic acids on the pharmacokinetics of a PEGylated erythropoietin.
    Liu L; Li H; Hamilton SR; Gomathinayagam S; Rayfield WJ; van Maanen M; Yin KC; Hong L; Prueksaritanont T
    J Pharm Sci; 2012 Dec; 101(12):4414-8. PubMed ID: 22987365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.
    Hu J; Duppatla V; Harth S; Schmitz W; Sebald W
    Bioconjug Chem; 2010 Oct; 21(10):1762-72. PubMed ID: 20886828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the combined effects of pegylation and glycosylation on the stability of erythropoietin using a stability-indicating SE-HPLC.
    Abed HS; Al-Ghobashy MA; Fathalla FA; Salem MY
    Biologicals; 2017 Nov; 50():129-136. PubMed ID: 28958787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specific PEGylation of human thyroid stimulating hormone to prolong duration of action.
    Qiu H; Boudanova E; Park A; Bird JJ; Honey DM; Zarazinski C; Greene B; Kingsbury JS; Boucher S; Pollock J; McPherson JM; Pan CQ
    Bioconjug Chem; 2013 Mar; 24(3):408-18. PubMed ID: 23350694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone.
    Wu L; Chen J; Wu Y; Zhang B; Cai X; Zhang Z; Wang Y; Si L; Xu H; Zheng Y; Zhang C; Liang C; Li J; Zhang L; Zhang Q; Zhou D
    J Control Release; 2017 Mar; 249():84-93. PubMed ID: 28131652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration.
    Mcleod VM; Chan LJ; Ryan GM; Porter CJ; Kaminskas LM
    J Pharm Sci; 2015 Apr; 104(4):1421-30. PubMed ID: 25631360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative antibody Fab' fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering.
    Humphreys DP; Heywood SP; Henry A; Ait-Lhadj L; Antoniw P; Palframan R; Greenslade KJ; Carrington B; Reeks DG; Bowering LC; West S; Brand HA
    Protein Eng Des Sel; 2007 May; 20(5):227-34. PubMed ID: 17452434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.